Increased recognition of advantages, over the last decade, of minimizing surgical trauma by operating through smaller incisions and its direct impact on reduced postoperative pain, quicker recovery, improved cosmesis and earlier return to work has spurred the minimally invasive cardiac surgical revolution. This transition began in the early 1990s with advancements in endoscopic instruments, video & fiberoptic technology and improvements in perfusion systems for establishing cardiopulmonary bypass (CPB) via peripheral cannulation (2-8). Society of Thoracic Surgeons data documents that 20% of all mitral valve surgeries are performed using minimally invasive techniques, with half being robotically assisted. This article reviews the current status of robotically assisted mitral valve surgery, its advantages and technical modifications for optimizing clinical outcomes.

**KEYWORDS**
Robotic; mitral valve surgery; mitral valve repair; minimal access; minimally invasive
During robotically assisted procedures the surgeon sits on a separate console and manipulates mechanical wrists that allow seven degrees of multidirectional motion. The bedside team, comprising of assistant and nurses, help in exchange of instruments and handing sutures/retrieval of needles. The robotic system will transmit the scaled movements of the surgeon to the robotic arms and the computer corrects for surgical tremors. Figure 1 shows typical setup for a robotically assisted mitral valve repair. Enhanced 3-D visualization of the valve from the console is provided by two parallel camera arms, controlled by the surgeon. Moreover, the use of a dynamic atrial retractor (10) with the robotic platform allows for rapid and continuous retractor repositioning to maximize valve exposure providing an additional advantage over traditional endoscopic approaches. The lack of tactile feedback with robotic procedures is still a limitation, leaving the surgeon to rely on visual cues to determine tissue strain. Potential difficulties with robotic knot-tying is a negative aspect associated with robotic surgery however advent of the Cor-Knot™ and prelooped Leyla sutures (11) as employed by our group have significantly simplified this problem and reduced operative times. The Cor-Knot™ device (LSI Solutions, Inc., Victor, NY) uses a titanium clip to secure sutures, eliminating intra-cardiac knot tying and reducing operative times. Between May 2000 and December 2012, 800 patients underwent robotically assisted mitral valve surgery at our institution. The mean age was 59.7±12.1 years. The mean Cor-Knot™ device time for annuloplasty deployment was significantly shorter when compared with robotic knot-tying. Furthermore annuloplasty band placement time, CPB and cross-clamp times also were significantly shorter in the Cor-Knot™ cohort and we concluded that compared to intra-cardiac robotic suture tying, the Cor-Knot™ device shortens all operative times significantly. The mean annuloplasty band placement time was reduced by 10 minutes.

The first robotic-assisted mitral valve surgery was performed in France by Carpentier and colleagues (12) in 1997 using a prototype of the current da Vinci robotic system (Intuitive Surgical, Sunnyvale, CA). Dr Chitwood led the team from East Carolina University in 2000 with the first robotic mitral valve case in the United States (13). In 2002 the Food and Drug Administration provided approval of the da Vinci system for use in cardiac surgery following the pivotal multicenter trial led by Drs. Nifong and Chitwood from the East Carolina University (14).

As the surgical teams worldwide have continued to learn and enhance their experience with this technology, subsequent publications have consistently shown improved recovery times and less pain, associated with robotically assisted procedures (15-18). In a series by Murphy and colleagues (19), more than 60% of robotically assisted mitral valve surgery patients were discharged within 4 days of surgery. In the most recently published meta-analysis from Cheng and colleagues (20), a statistically significant reduction in bleeding, transfusion, incidence of atrial fibrillation, and time to resumption of normal activities was shown when comparing minimally invasive mitral valve surgery with conventional mitral surgery.

An added measure of confidence in this technology comes from the fact that all the above benefits accrue without compromising the quality of outcomes or the durability of mitral valve repair. In the available meta-analyses, perioperative and long-term mortality were equivalent between techniques for mitral valve surgery, as was long-term freedom from reoperations (15,20,21). These findings are supported by two large single-center outcomes studies. Eight-year freedom from reoperation was better as was short-term and 1-year survival (22,23). The largest single-center report of robotically assisted mitral valve surgery comes from our group at the East Carolina Heart Institute (24) which showed a low short and long term mortality of 0.4% and 1.7% respectively in 540 consecutive patients with a 2.9% reoperation rate. These results compared favorably with the meta-analysis published by Cheng et al. (20), in which 30-day mortality was 1.2% and reoperation rate was 2.3%.

However, a significant learning curve exists with the use of robotically assisted mitral valve surgery (25). Both Cheng and colleagues (26) and our group (27) showed a decrease in mitral valve repair failure rate only after 74 and 100 robotic-assisted cases respectively. Operative times, including the cardiopulmonary and aortic cross-clamp times have also been shown to be longer with robotically assisted minimally invasive mitral valve procedures compared with sternotomy approach (20).

One should be cognizant of the fact that most series of minimally invasive procedures including mitral valve surgery are carefully selected and when comparing outcomes (non-randomized) between robotically assisted mitral valve surgery and conventional surgery, acknowledgement of selection bias will be critical. For example, patients with significant peripheral vascular disease are more likely to be excluded from consideration for robotically assisted minimally invasive mitral valve surgery. In the meta-analysis of Cheng and colleagues (20), patients were younger and had a lower incidence of baseline renal failure and pulmonary disease.
Majority of preoperative evaluation of patients for robotic mitral valve procedures follows along the lines of patients undergoing standard mitral valve surgery with a few notable exceptions. The need for peripheral cannulation for establishing CPB leads to the most important difference. There is increasing support for the role of computed tomography angiography (CTA) of the vascular tree in preoperative assessment of patients being considered for peripheral cannulation. In a study of 141 patients, scheduled for minimally invasive cardiac surgery including robotic procedures at the Cleveland Clinic, 20% patients had their surgical approach changed to sternotomy because of CTA findings related to significant aorto-iliac atherosclerosis and mitral annular calcification (28). Previous right chest surgery or adhesions and presence of breast implants are additional issues which might preclude a robotically assisted procedure. At East Carolina University, we obtain preoperative pulmonary function (PFT) testing in patients with history of COPD and will follow it with right heart catheterization, if needed, because combination of impaired PFT, pulmonary hypertension and impaired right heart function increases the chances of postoperative right heart dysfunction and unilateral pulmonary edema. Lung function tests will also tell us about the patient’s ability to tolerate single lung ventilation.

Patient positioning is typically supine with the right upper trunk elevated (Figure 2). The right arm is positioned at the side to allow the shoulder to drop down to improve surgical exposure. The surgical team should appropriately support the right shoulder to avoid stress on the brachial plexus and the neck. External defibrillator pads should be applied correctly and connected before starting the procedure. The right lung can be reexpanded to attempt enhancement of defibrillation efficacy. The robotic arms should be withdrawn prior to defibrillation to prevent iatrogenic injury.

Robotic mitral valve surgery utilizes right anterolateral thoracotomy approach and hence lung isolation has been a mainstay of anesthetic management. The right lung is typically deflated as the surgeon enters the chest cavity and opens the pericardium to expose the left atrium before the initiation of CPB. Single lung ventilation is also typically used at certain points after separation from bypass: as surgical sites are checked, bleeding is controlled, and the chest closed.

The most common techniques for achieving lung isolation are with a left-sided double-lumen tube (DLT) or a right-sided bronchial blocker placed through a standard single-lumen endotracheal tube. Abnormalities (FEV1 <40% predicted, DLCO <40% predicted) in preoperative lung function tests should alert the surgeon regarding potential problems with single lung ventilation during surgery and the patient should have been counseled appropriately.

The importance of transesophageal echocardiography (TEE) to help guide clinical decision making in cardiac surgery has been well established particularly in the setting of mitral valve repair (29-31). TEE is intricately involved in guiding surgical cannulation, monitoring hemodynamics, and assessing the mitral valve before and after intervention in robotically aided mitral valve surgeries and is an essential tool for the team planning to embark on such operations (32). Planning the MV repair with quantitative mitral valve modeling using 3D echo has been a very useful adjunct (33). TEE will also alert us of presence of aortic regurgitation and left ventricular hypertrophy, both of which warrant adjustment in myocardial preservation strategy. Figure 3 illustrates the anesthetic preparation and monitoring, typical for such cases including double lumen endotracheal tube, TEE probe, Swan Ganz catheter and the right internal jugular (IJ) superior vena cava (SVC) cannula (17 Fr Biomedicus arterial).

**Vascular access & management of CPB**

Venous return to the CPB circuit can be achieved in several ways. There are various commercially available long percutaneous venous return cannulas (22F-28F) that may be introduced up to
Figure 4. Right groin femoral arterial (thin arrow) and femoral venous (thicker arrow) cannulae. The femoral venous cannula is positioned in the right atrium using TEE guidance.

Figure 5. Setup for monitoring the peripheral leg saturations during the case.

The right atrium via the femoral venous system. After accessing the femoral vein, a long wire is advanced under TEE guidance into the right atrium. The venous cannula is then advanced over the wire into the right atrium with TEE confirmation. The SVC cannula is placed via the right IJ vein, under TEE guidance. Figures 3 & 4 demonstrate the neck and the groin venous cannulae in place.

Adjunctive measures such as vacuum assistance are used to assist venous drainage when using long percutaneous cannulae and can increase flow dynamics by 20% to 40% (34). In fact, adequate total body venous drainage may be achieved with a single femoral venous cannula as long as the cannula’s multi-orificed side ports reside in the body of the right atrium with the tip in the proximal SVC. In our practice it is standard to place an additional percutaneous venous drainage cannula that resides in the SVC from the neck (Figure 3) and is positioned 2 cm proximal to the SVC-right atrial junction. This placement is best achieved via the right IJ vein given the near direct path it takes to the SVC.

The placement of a large-bore drainage catheter in the neck is not without substantial risk of vascular injury. Perforation of the right atrium, vena cava, or other vascular structure within the pericardium can lead to pericardial tamponade. Use of a strict Seldinger technique to minimize the chance of wire kinking during catheter advancement and use of TEE guidance for both wire and cannula placement is critical components for improving safety (35). Placement is facilitated by use of sequential dilators of increasing size in advance of the cannula. Ideally an assistant with sterile gown and gloves should be present.

A small dose of heparin should be administered just before IJ cannula placement. The cannula should then be flushed vigorously after it is secured to prevent any clotting or thrombus formation within it. Sutures may be placed around the cannulation site at this point or later, to facilitate closure of the defect and provide hemostasis upon cannula removal. When the right atrium must be opened during robotic mitral valve surgery (i.e., concomitant tricuspid valve repair), bicaval cannulation and occlusion are typically used to prevent associated air entrainment with an exposed right atrium. When the SVC is occluded, continuous monitoring of right IJ pressure is important to help ensure adequate SVC drainage from a percutaneous cannula.

Regardless of whether arterial outflow from the CPB circuit is achieved via percutaneous peripheral (Figure 4), or even direct central cannulation, use of TEE in guiding proper placement is key. We monitor the saturations of both the feet, in cases employing peripheral cannulation, using the NIRS probe (INVOS® Cerebral/Somatic oximeter) and a dual chamber monitor to record both cerebral and leg saturations simultaneously (Figure 5). A significant drop in peripheral saturation during the case (to <20% baseline) will prompt us to consider shunting the leg with a 5 Fr sheath introduced into the femoral artery distal to the cannulation site. The inflow to this shunt is through a 3 way tap pre-connected to the arterial cannula. This practice has allowed us to prevent any cases of significant limb ischemia in our series of patients.

Several complications associated with vascular access and retrograde arterial perfusion have been reported by Mohr and colleagues (36) with Port Access surgery. New York University Hospital describes an institutional drop in neurologic events from 4.7% to 1.2% during minimally invasive valvular surgical procedures, which they attribute to the avoidance of peripheral aortic cannulation (37). Murphy and colleagues (19) report the use of a screening protocol to identify and avoid femoral cannulation in patients considered at higher risk for retrograde embolization.

Regardless of approach, as already discussed, during aortic cannulation with Seldinger technique, the wire should be clearly observed on TEE to be intraluminal in the aorta prior. An elevation of arterial outflow-line pressure on the CPB circuit is often the first sign of aortic dissection. Immediate evaluation of the descending aorta with TEE should be made to rule out dissection. Unlike with standard direct surgical cannulation, retrograde aortic dissection may not be apparent in the surgical field until it extends up to the ascending aorta. Early recognition and conversion to antegrade central arterial flow may limit the damage of this potentially devastating complication.
Our preferred method for cross clamping the aorta is the angled Chitwood Transhthoracic Aortic Cross Clamp (Scanlan International Inc, Minneapolis, MN), which is inserted percutaneously (Figure 6) and guided toward the ascending aorta under direct or endoscopic vision. Use of this technique over Port Access for aortic cross-clamping is based on several factors, not the least of which are decreases in infrastructure demands and costs (38) as well as shorter operative and cross-clamp times. A disadvantage is the need to place a separate aortic root vent percutaneously onto the ascending aorta for cardiac venting and antegrade cardioplegia administration. Figure 7 demonstrates the Chitwood clamp and the proximal aortic root vent cardioplegia cannula in place.

The Port Access system (Edwards Lifesciences, Irvine, CA) was designed to facilitate minimal access cardiac surgery and was introduced into clinical practice in 1997. A similar product is also produced by Estech (Danville, CA). At the cornerstone of this new technology was the development of the EndoClamp Aortic Catheter (Edwards Lifesciences), which is an endoluminal aortic balloon. The EndoClamp is placed through a side port of a Y-shaped large (21F or 24F) arterial cannula (EndoReturn Arterial Cannula) and advanced into the ascending aorta. This maneuver requires significant TEE guidance and a constant vigilance to look for balloon migration and malperfusion.

When evaluating studies comparing the overall safety of the two approaches, it is important to consider the more significant learning curve associated with Port Access surgery. The steepness of the curve was exemplified by the findings of the first Port Access International Registry, in which the incidence of iatrogenic aortic dissection was 1.3% in the first half of the study followed by a decrease to 0.2% in the second half (39).

Other alternatives to aortic cross-clamping exist, the simplest of which involves operating on a beating heart. The obvious advantage of this method is that it allows coronary flow to remain mostly uninterrupted. Disadvantages of this approach include a more disturbed surgical field and the possibility of systemic air embolization. In redo procedures or in presence of mild-moderate aortic insufficiency we have used cold fibrillatory arrest without aortic cross clamping with satisfactory results. One has to be cognizant about manipulating the left atrial retractor carefully and avoid worsening the aortic regurgitation. Fibrillation can be achieved either by a fibrillator applied directly to the heart or through the use of a pacing Swan Ganz catheter (40).

**Cardioplegia delivery & solution of choice**

We use a long combined aortic root vent cardioplegia cannula inserted directly through the working port incision across a 3-0 Gortex pursestring, securing it in the proximal ascending aorta for antegrade cardioplegia administration during our robotic cases.

An additional option is the use of a percutaneous coronary sinus catheter (41,42). The EndoPledge Coronary Sinus Catheter (Edwards Lifesciences) is advanced through an 11F introducer sheath, typically via the right IJ vein. The EndoPledge is a long triple-lumen catheter with a balloon on the end that allows for occlusion of the coronary sinus, measurement of distal pressure, and the infusion of cardioplegia. The obvious advantage of this approach is the ability to administer retrograde protection while remaining completely endoscopic. EndoPledge cannulation can be guided by TEE, fluoroscopy, or both. TEE is most commonly used to help direct the cannula into the coronary sinus ostia. Once in the coronary sinus, TEE is limited in its ability to exactly define the position of the tip, and provides limited functional information. The generation of a “ventricularized” distal pressure waveform during inflation of the occlusion balloon suggests adequate sinus occlusion. The cannula should be advanced until this ventricularized waveform is seen with balloon inflation. The cannula is deemed to be inserted too far if ventricularization occurs with less than 0.75 to 1 mL of balloon inflation and not far enough if more than 1 mL is
required for occlusion.

Though conceptually appealing, the use of the EndoPledge cannula has not been widely adopted with robotic aided surgeries. Concerns about coronary sinus perforation risk, increased complexity of placement, and a high rate of dislodgment have limited its adoption. However the most important reason for avoidance of the EndoPledge cannula is that many surgeons do not believe that retrograde cardioplegia is necessary for cardiac protection when adequate antegrade cardioplegia can be delivered; this has been demonstrated in several case series (43,44).

Our preferred cardioplegia solution for robotically assisted mitral valve surgery is Custodiol® HTK Solution. As a crystalloid solution, Custodiol® HTK Solution is considered an intracellular solution, containing low concentrations of the electrolytes sodium, calcium, potassium and magnesium. It contains a high concentration of an amino acid buffering agent, histidine/histidine hydrochloride, the amino acid tryptophan a-ketoglutarate, and the osmotic agent mannitol. The histidine/ histidine hydrochloride buffering system provides normal osmolarity and enhances the solution’s buffering capacity. A single cold 2-2.5 L dose allows electromechanical silence for upto an hour and allows surgeon to focus on surgery uninterrupted. The infusate should be administered slowly over 10-15 minutes. Top up doses of 100-300 cc may be administered on return of ECG activity or after an hour of ischemia time. The large volume low sodium infusate in Custodiol® HTK often drops the serum sodium and pH and the perfusionists needs to pay attention to correct them. Standard blood cardioplegia is still a viable alternative however the need to interrupt surgery for frequent top-up and increased chance of instilling air into the coronaries during the top-up dose instillation down an air filled aortic root are reasons for our team switching to Custodiol® HTK in line with the safety and efficacy data published (45).

Robotic assisted mitral valve surgery in redo situations

Previous cardiac surgery does not preclude robotic approach and in fact, in well selected patients may provide some significant advantages. Multiple studies have shown at least equal if not better mortality with redo right thoracotomy approach in comparison with redo sternotomy mitral valve surgery (46-48). Reduction in infection rate, transfusion requirement, and length of hospital stay were consistently shown in these studies. The Cleveland Clinic group reported a higher incidence of repair failure and stroke in 80 redo right thoracotomy approach mitral valve surgery patients compared with a similar group of 2,444 reoperative mitral repair, performed via sternotomy approach. Mortality between the two groups was similar (6.7% and 6.3%) (49). At East Carolina University, our group (49) reported a 3% thirty day mortality in 167 patients with previous sternotomy operated using right anterolateral thoracotomy approach over a 15 year period. This series comprised of 19 robotic cases. During the last five years examined, the 30-day mortality dropped to 0% in 85 patients with a low stroke rate. A higher than expected incidence of pneumonia, with 28% isolated to the right lung was noted in this series.

Management of patients with patent left internal mammary (LIMA) coronary bypass grafts requires some mention, although in practice it differs little from patients undergoing sternotomy. The ability to clamp the LIMA and prevent myocardial warming is limited, thus management strategies revolve around more aggressive systemic cooling or “beating-heart” surgical strategies (49-51).

The presence of anterior chest-wall adhesions from previous sternotomy may limit exposure to the right ventricle, preventing the ability to apply temporary epicardial pacing wires, and this may be particularly true when performing true endoscopic surgery. The preoperative placement of a pacing Swan Ganz catheter can alleviate this problem. Similarly, the combination of previous cardiac surgery and robotic cardiac surgery may also create difficulties in achieving caval occlusion if the right side of the heart must be entered. Placement of endoscopic bulldog clips on each cava during robotic aided surgery has also been reported (52). Aggressive use of assisted venous drainage, with a hard shell venous reservoir in the CPB circuit and the venous cannulae withdrawn into the IVC and SVC can also help manage the situation without recourse to caval occlusion.

Mitral valve exposure and repair

Exposure and visualization of the mitral valve during robotic surgery varies from the standard sternotomy approach and has been detailed in our previous publications (24). Specialized left atrial retractors have been developed to expose the mitral valve (Figure 8). We measure the anterior mitral valve leaflet to confirm the size of annuloplasty ring that we will use (Figure 9). Our current practice at East Carolina Heart Institute is to first perform the leaflet repair. Over the years we have moved from away from extensive resections to current practice of respecting the leaflet integrity. We excise the minimal amount of prolapsing leaflet segment tissue “Haircut resection technique” (53) ensuring that no part of the reconstructed leaflet is unsupported by chord (Figures 10,11). If need be, we will re-implant/transfer chords or insert Gortex neo-chords to support the leaflet segment. Subsequently we will complete the ring implantation using interrupted suture technique. We progress by securing each suture with Cor-Knot™ before moving to the next annuloplasty suture (Figure 12). Following ring implantation we will perform saline testing to check valve competence and then tighten the foldoplasty/neo-chord sutures. The robotic video imaging system greatly enhances field lighting and visualization of the mitral valve. Figure 13 shows a competent valve after repair with a well seated ring secured by Cor-Knot™. The additional
Figure 8. Dynamic left atrial retractor (arrow) being inserted across the left atriotomy.

Figure 9. Intraoperative view with left atrial retractor deployed (thin arrow) and the anterior leaflet height being measured, with a measuring stick (thick arrow) before confirming the annuloplasty ring size.

Figure 10. “Haircut” P2 resection being performed.

Figure 11. Leaflet repair being performed with 4-0 Cardioneal sutures, after resection.

Figure 12. Intraoperative view showing annuloplasty ring being secured with Cor-Knot™ (arrow).

Figure 13. Intraoperative view of a competent mitral valve repaired using robotic assistance.

monitors in the operating room allow all members of the operative team to observe and even participate in the mitral valve repair.

**Weaning from CPB and transfer to ICU**

During separation from CPB, in principle there are no dramatic differences from open operations. However, if increased cross-clamp and CPB times occur, this may need to be factored into decision making regarding post-CPB pharmacologic, ventilatory, fluid, and blood-product management. After a period of reperfusion, preparations are made and any requirements for pacing and hemodynamic support are adjusted. If a pacing PAC
is being used, adjustments in position may need to be made because once the heart fills, the wire may migrate away from the ventricular wall. The amplitude may also need to be increased if the ventricular pacing threshold has increased. Initial ventilation of both lungs should be instituted when possible. Attempts to de-air the heart are made in the usual fashion. The ability to dislodge retained left atrial air is typically not hampered by the incision, but exposure of the left ventricular apex may be. Consideration for leaving a LV vent across the mitral valve should be made in patients with pre-existing aortic regurgitation especially in those with mild degree of LV impairment/ hypertrophy.

Given the close proximity of the noncoronary leaflet of the aortic valve to the anterior mitral valve annulus, a directed TEE examination of the aortic valve after CPB is also important. Similarly, the proximity of the circumflex coronary artery to the posterior and lateral annulus requires assessment of ventricular wall motion. The patency of right sided pulmonary veins should be checked before separation from bypass and similarly presence of a freely moving PAC is mandatory before discontinuation of CPB.

During the initiation of surgical chest closure, single lung ventilation is typically needed. Superimposing this additional strain on the right ventricle in patients with preexisting dysfunction or residual myocardial stunning may lead to decompensation. Measures such as positive end-expiratory pressure to the ventilated lung or intermittent lung inflation may be necessary.

At the conclusion of surgery there are several preparations the anesthesia team must make before transport that are not usually necessary following sternotomy. First, if a double-lumen endotracheal tube has been used, it should be switched to a single lumen tube. The use of an airway-exchange catheter may be helpful. Adequate hemostasis should be secured at the RIJ SVC cannulation site, usually with a box stitch.

Adequacy of peripheral pulses on the side of cannulated femoral artery should be checked before leaving the room.

Postoperative pain management

Although many of the patients for robotic mitral valve surgery are excellent candidates for early extubation, caution must still be exercised because of the potential occurrence of significant postoperative chest-wall bleeding, given the multiple chest-wall puncture sites.

The simplest adjunctive pain-management technique involves the use of limited intercostal injections of local anesthetic during surgical closure. The desire for a longer duration of local anesthesia has led many to use continuous infusions via temporary catheters and specialized pumps. Catheters may simply be left under the subcutaneous tissue before closure and then tunneled out through the skin (54,55). An extrapleural intercostal catheter can also be placed under direct vision, and may also provide improvements in pain control and, possibly, pulmonary function (56). The inability to adequately strip the parietal pleura posteriorly beyond the incision may limit optimal positioning of the catheter tip.

Conclusions

Robotically aided mitral valve surgery is rapidly becoming the “gold-standard” and its outcomes are being proposed for use as benchmark for valve repair quality related outcome measures (57). Patients are experiencing a decrease in pain and faster recoveries without sacrificing the durability of their surgical repair. Most importantly, these results can be achieved with an equivalent morbidity and mortality in comparison with standard mitral valve surgery. The recent publication from the Mayo Clinic group (58) also suggests that with systems engineering approach, even a capital intensive technique like robotic mitral valve surgery can be made cost effective. At present, the majority of robotic cases are performed at only a few centers of excellence and although definitive advantages of robotic surgery over non-robotic-assisted minimally invasive surgery have yet to be shown, expansion of robotic aided minimally invasive cardiac surgery seems inevitable, fueled by continued technological advancements and patient demands. It is important to acknowledge that consistent successful outcomes require a significant investment in training and experience for the whole “robotic team”.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References


